Open an account

InflaRx NV

IFRX · NASDAQ

$1.54+$0.09 (+6.21%)TodayMarket closed ·
Prev close $1.45

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 65 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

Employees
65
Headquarters
Jena, Thueringen
Listed
Nov 8, 2017
Sector
Health Care
Industry
Biotechnology
Website
inflarx.de

IFRX key statistics

Market cap
226.95M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
691.57K
Volume
724.09K
Open price
$1.45
High today
$1.61
Low today
$1.44
52 Week high
$2.95
52 Week low
$0.7984

InflaRx NV (IFRX) at a glance

InflaRx NV (IFRX) last traded at $1.54, with a market cap of 226.95M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.44 and $1.61. The current price is 6.9% above the day's low and 4.3% below its high.

Volume so far is 724.09K shares, in line with the average of 691.57K shares a day.

Over the past year InflaRx NV has ranged from $0.7984 to $2.95, and now sits 34% of the way up that range.

InflaRx NV met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.09 per share against an estimate of -$0.0595.

The average analyst price target is $8.05, 422.5% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

83%of 6 analyst ratings say Buy
  • Buy83.3%
  • Hold16.7%
  • Sell0.0%
Price target · 11 analystsAvg $8.05
Low
$3.03
Now
$1.54
High
$14.70

IFRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 33.8% on average.

  1. Q3 FY24: reported -$0.30 per share against an estimate of -$0.255
  2. Q4 FY24: reported -$0.08 per share against an estimate of -$0.255
  3. Q1 FY25: reported -$0.13 per share against an estimate of -$0.1877
  4. Q2 FY25: reported -$0.21 per share against an estimate of -$0.1887
  5. Q3 FY25: reported -$0.18 per share against an estimate of -$0.1545
  6. Q4 FY25: reported -$0.15 per share against an estimate of -$0.153
  7. Q1 FY26: reported -$0.08 per share against an estimate of -$0.1207
  8. Q2 FY26: reported -$0.09 per share against an estimate of -$0.0595

IFRX news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Vandana Singh

    Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

Similar companies

Companies in the same industry as InflaRx NV

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.